SlideShare a Scribd company logo
SMARTube™ HIV&HCV
for early diagnosis of virus
infections with long
seronegative window period
January 2016
© 2016 SMART Biotech Ltd
• The “Window Period” is the time between primary infection and
when a test can reliably detect that infection.
• In antibody-based assays, the window period (a.k.a.
Seroconversion Time) is the time that the body takes to
produce measurable amounts of antibodies after infection.
• If serology test is taken during the window period, it will be
negative since antibodies are not yet present at a detectable level.
• HIV: 95% 3 months (30-90 days).
• HCV: 95% 6 months (80-180 days).
• However, the infected (but unaware about his status) person
may transmit HCV, or HIV, to others during that period.
Window Period
S timulating
M aximal
A ntibody
R esponse
Tube
The solution:
SMARTube™ HIV&HCV
Тест на
антитела
SMARTube is a pre-analytical medical device for
blood sample improving before AB analysis
The solution:
SMARTube™ HIV&HCV
ELISA
Western Blot
Repitest
The time line from HIV infection to
seroconversion
• All the different diagnostic tests are antibody based (e.g. ELISA) testing.
• Seroconversion is the point of HIV diagnosis, i.e. when the body
produces measurable amounts of antibodies
• The other methods detect the virus in the blood days before
seroconversion:
- PCR/NAT – can shorten the window period by 10-12 days.
- Antigen Tests (p24) – can shorten the window period by a week
The time line from HCV infection to
seroconversion
• All the different diagnostic tests are antibody based (e.g. ELISA) testing.
• Seroconversion is the point of HIV diagnosis, i.e. when the body
produces measurable amounts of antibodies
• The other methods detect the virus in the blood days before
seroconversion:
- PCR/NAT – can shorten the window period by 8 week
- Antigen Tests (p24) – can shorten the window period by a 6 weeks
The solution: SMARTube™
SMARTube™ closes the Window Period - the vast majority
of the infected people can be
detected within a week from the day of infection
HCV window Period With
SMARTube™
• CE mark.
• Israel.
• Nigeria.
• Russian Federation.
• South Africa.
• Turkey.
• Romania.
• Registration in process in several additional
countries (Including USA-FDA).
• Implementation in testing protocols of FHI and
IAVI.
• In Process with UN/ WHO/ IFRC.
Registration
Clinical Data
• Israel
• Russian Federation
• Hungary
• Romania
• China
• South Africa
• Kenya
• Mexico
• Turkey
Thank you

More Related Content

Viewers also liked

Presentation10
Presentation10Presentation10
Ofício nº 106 2014 pdf
Ofício nº 106 2014 pdfOfício nº 106 2014 pdf
Ofício nº 106 2014 pdf
Rogerio Catanese
 
Mancias
ManciasMancias
Pdf2004
Pdf2004Pdf2004
Pdf2004
observadescen
 
8 anolp aluno2caderno de apoio didático de lp - aluno - rj
8 anolp aluno2caderno de apoio didático de lp - aluno - rj8 anolp aluno2caderno de apoio didático de lp - aluno - rj
8 anolp aluno2caderno de apoio didático de lp - aluno - rj
elannialins
 
карта мышления
карта мышлениякарта мышления
карта мышленияkirovaevgenia
 
Definicion e importancia
Definicion e importanciaDefinicion e importancia
Definicion e importancia
MARISITAP BEBE Palomino Hurtado
 
Apresentação2
Apresentação2Apresentação2
Apresentação2
FBIRF1
 
Rolas en El Mañanero.
Rolas en El Mañanero.Rolas en El Mañanero.
Rolas en El Mañanero.
Brozo Xmiswebs
 
Direitos autorais fgv
Direitos autorais fgvDireitos autorais fgv
Direitos autorais fgvKarlla Costa
 
Cuadro comparativo
Cuadro comparativoCuadro comparativo
Cuadro comparativo
José Ramos
 
Publicidade FastFood
Publicidade FastFoodPublicidade FastFood
Publicidade FastFood
Edgar Costa
 
Primaverasept12
Primaverasept12Primaverasept12
Primaverasept12TV21
 
''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.
''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.
''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.
founder of Think zone bengal and Prometheuse
 
Xenos Car Entertainment System
Xenos Car Entertainment SystemXenos Car Entertainment System
Xenos Car Entertainment System
Rohit Singh
 
Instrução normativa nº 14.2008
Instrução normativa nº 14.2008Instrução normativa nº 14.2008
Instrução normativa nº 14.2008
elannialins
 
Disccuciones Foro bosque-nativo
Disccuciones Foro bosque-nativoDisccuciones Foro bosque-nativo
Disccuciones Foro bosque-nativo
Foro Abierto
 

Viewers also liked (20)

Presentation10
Presentation10Presentation10
Presentation10
 
Ofício nº 106 2014 pdf
Ofício nº 106 2014 pdfOfício nº 106 2014 pdf
Ofício nº 106 2014 pdf
 
Mancias
ManciasMancias
Mancias
 
Pdf2004
Pdf2004Pdf2004
Pdf2004
 
8 anolp aluno2caderno de apoio didático de lp - aluno - rj
8 anolp aluno2caderno de apoio didático de lp - aluno - rj8 anolp aluno2caderno de apoio didático de lp - aluno - rj
8 anolp aluno2caderno de apoio didático de lp - aluno - rj
 
карта мышления
карта мышлениякарта мышления
карта мышления
 
Monty Roberts
Monty RobertsMonty Roberts
Monty Roberts
 
Definicion e importancia
Definicion e importanciaDefinicion e importancia
Definicion e importancia
 
Apresentação2
Apresentação2Apresentação2
Apresentação2
 
Rolas en El Mañanero.
Rolas en El Mañanero.Rolas en El Mañanero.
Rolas en El Mañanero.
 
Direitos autorais fgv
Direitos autorais fgvDireitos autorais fgv
Direitos autorais fgv
 
Cuadro comparativo
Cuadro comparativoCuadro comparativo
Cuadro comparativo
 
Konica Minolta - Lanyon
Konica Minolta - LanyonKonica Minolta - Lanyon
Konica Minolta - Lanyon
 
Publicidade FastFood
Publicidade FastFoodPublicidade FastFood
Publicidade FastFood
 
Primaverasept12
Primaverasept12Primaverasept12
Primaverasept12
 
''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.
''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.
''QUIZ-RUSH''.. BIG QUIZ BY THINK ZONE.
 
Xenos Car Entertainment System
Xenos Car Entertainment SystemXenos Car Entertainment System
Xenos Car Entertainment System
 
Jornada 10
Jornada 10Jornada 10
Jornada 10
 
Instrução normativa nº 14.2008
Instrução normativa nº 14.2008Instrução normativa nº 14.2008
Instrução normativa nº 14.2008
 
Disccuciones Foro bosque-nativo
Disccuciones Foro bosque-nativoDisccuciones Foro bosque-nativo
Disccuciones Foro bosque-nativo
 

Similar to SMART 2016_En General

Smart tube intro & faqs
Smart tube intro & faqsSmart tube intro & faqs
Smart tube intro & faqs
Neeraj Mahajan
 
01.04 laboratory diagnosis and monitoring of hiv infection
01.04 laboratory diagnosis and monitoring of hiv infection01.04 laboratory diagnosis and monitoring of hiv infection
01.04 laboratory diagnosis and monitoring of hiv infection
David Ngogoyo
 
Know Your COVID Test
Know Your COVID TestKnow Your COVID Test
Know Your COVID Test
Ashutosh Mishra
 
HIV MANAGEMENT
HIV MANAGEMENT HIV MANAGEMENT
HIV MANAGEMENT
Praba Karan
 
Covid-19 Testing
Covid-19 TestingCovid-19 Testing
Covid-19 Testing
PrashantSharma962
 
NAAT IN BLOOD BANKING
NAAT IN BLOOD BANKINGNAAT IN BLOOD BANKING
NAAT IN BLOOD BANKING
Narmada Tiwari
 
Diagnosis of COVID-19
Diagnosis of COVID-19Diagnosis of COVID-19
Diagnosis of COVID-19
Dr. Anuja Joshi
 
Ppt2.hiv testing technologies
Ppt2.hiv testing technologiesPpt2.hiv testing technologies
Ppt2.hiv testing technologies
Gugsa Germossa
 
The role of the clinical lab in diagnosis of hiv
The role of the clinical lab in diagnosis of hivThe role of the clinical lab in diagnosis of hiv
The role of the clinical lab in diagnosis of hiv
Ayman Allam
 
Smar tube intro & faqs
Smar tube intro & faqsSmar tube intro & faqs
Smar tube intro & faqs
Neeraj Mahajan
 
Measles Disease.pptx
Measles Disease.pptxMeasles Disease.pptx
Measles Disease.pptx
VivianBuberwa
 
3. Diagnosis of HIV Infection ICAPRev.pptx
3. Diagnosis of HIV Infection ICAPRev.pptx3. Diagnosis of HIV Infection ICAPRev.pptx
3. Diagnosis of HIV Infection ICAPRev.pptx
yakemichael
 
Rapid detection of hepatitis c (ora quick)
Rapid detection of hepatitis c (ora quick)Rapid detection of hepatitis c (ora quick)
Rapid detection of hepatitis c (ora quick)
Said Al Jaafari
 
POCT Innovation Dpp
POCT Innovation DppPOCT Innovation Dpp
POCT Innovation Dpp
Talita Franco-Salles
 
Post exposure prophylaxis of hiv
Post exposure prophylaxis of hivPost exposure prophylaxis of hiv
Post exposure prophylaxis of hiv
Niranjan Chavan
 
Diseases transmitted thru blood.pptx hematology
Diseases transmitted thru blood.pptx hematologyDiseases transmitted thru blood.pptx hematology
Diseases transmitted thru blood.pptx hematology
MugombaJulius
 
OS16 - 1.4.f A Process Modelling Approach to Estimate FMD Diagnostic Capaci...
OS16 - 1.4.f   A Process Modelling Approach to Estimate FMD Diagnostic Capaci...OS16 - 1.4.f   A Process Modelling Approach to Estimate FMD Diagnostic Capaci...
OS16 - 1.4.f A Process Modelling Approach to Estimate FMD Diagnostic Capaci...
EuFMD
 
Laboratory diagnosis and monitoring of HIV
Laboratory diagnosis and monitoring of HIV Laboratory diagnosis and monitoring of HIV
Laboratory diagnosis and monitoring of HIV
Thet Su Wynn
 
Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...
Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...
Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...
John Blue
 
Hiv test (final)
Hiv test (final)Hiv test (final)
Hiv test (final)
Samairah Alia
 

Similar to SMART 2016_En General (20)

Smart tube intro & faqs
Smart tube intro & faqsSmart tube intro & faqs
Smart tube intro & faqs
 
01.04 laboratory diagnosis and monitoring of hiv infection
01.04 laboratory diagnosis and monitoring of hiv infection01.04 laboratory diagnosis and monitoring of hiv infection
01.04 laboratory diagnosis and monitoring of hiv infection
 
Know Your COVID Test
Know Your COVID TestKnow Your COVID Test
Know Your COVID Test
 
HIV MANAGEMENT
HIV MANAGEMENT HIV MANAGEMENT
HIV MANAGEMENT
 
Covid-19 Testing
Covid-19 TestingCovid-19 Testing
Covid-19 Testing
 
NAAT IN BLOOD BANKING
NAAT IN BLOOD BANKINGNAAT IN BLOOD BANKING
NAAT IN BLOOD BANKING
 
Diagnosis of COVID-19
Diagnosis of COVID-19Diagnosis of COVID-19
Diagnosis of COVID-19
 
Ppt2.hiv testing technologies
Ppt2.hiv testing technologiesPpt2.hiv testing technologies
Ppt2.hiv testing technologies
 
The role of the clinical lab in diagnosis of hiv
The role of the clinical lab in diagnosis of hivThe role of the clinical lab in diagnosis of hiv
The role of the clinical lab in diagnosis of hiv
 
Smar tube intro & faqs
Smar tube intro & faqsSmar tube intro & faqs
Smar tube intro & faqs
 
Measles Disease.pptx
Measles Disease.pptxMeasles Disease.pptx
Measles Disease.pptx
 
3. Diagnosis of HIV Infection ICAPRev.pptx
3. Diagnosis of HIV Infection ICAPRev.pptx3. Diagnosis of HIV Infection ICAPRev.pptx
3. Diagnosis of HIV Infection ICAPRev.pptx
 
Rapid detection of hepatitis c (ora quick)
Rapid detection of hepatitis c (ora quick)Rapid detection of hepatitis c (ora quick)
Rapid detection of hepatitis c (ora quick)
 
POCT Innovation Dpp
POCT Innovation DppPOCT Innovation Dpp
POCT Innovation Dpp
 
Post exposure prophylaxis of hiv
Post exposure prophylaxis of hivPost exposure prophylaxis of hiv
Post exposure prophylaxis of hiv
 
Diseases transmitted thru blood.pptx hematology
Diseases transmitted thru blood.pptx hematologyDiseases transmitted thru blood.pptx hematology
Diseases transmitted thru blood.pptx hematology
 
OS16 - 1.4.f A Process Modelling Approach to Estimate FMD Diagnostic Capaci...
OS16 - 1.4.f   A Process Modelling Approach to Estimate FMD Diagnostic Capaci...OS16 - 1.4.f   A Process Modelling Approach to Estimate FMD Diagnostic Capaci...
OS16 - 1.4.f A Process Modelling Approach to Estimate FMD Diagnostic Capaci...
 
Laboratory diagnosis and monitoring of HIV
Laboratory diagnosis and monitoring of HIV Laboratory diagnosis and monitoring of HIV
Laboratory diagnosis and monitoring of HIV
 
Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...
Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...
Dr. Richard Kerr - Development of an Effective Pathogen Screening Program usi...
 
Hiv test (final)
Hiv test (final)Hiv test (final)
Hiv test (final)
 

SMART 2016_En General

  • 1. SMARTube™ HIV&HCV for early diagnosis of virus infections with long seronegative window period January 2016 © 2016 SMART Biotech Ltd
  • 2. • The “Window Period” is the time between primary infection and when a test can reliably detect that infection. • In antibody-based assays, the window period (a.k.a. Seroconversion Time) is the time that the body takes to produce measurable amounts of antibodies after infection. • If serology test is taken during the window period, it will be negative since antibodies are not yet present at a detectable level. • HIV: 95% 3 months (30-90 days). • HCV: 95% 6 months (80-180 days). • However, the infected (but unaware about his status) person may transmit HCV, or HIV, to others during that period. Window Period
  • 3. S timulating M aximal A ntibody R esponse Tube The solution: SMARTube™ HIV&HCV
  • 4. Тест на антитела SMARTube is a pre-analytical medical device for blood sample improving before AB analysis The solution: SMARTube™ HIV&HCV ELISA Western Blot Repitest
  • 5. The time line from HIV infection to seroconversion • All the different diagnostic tests are antibody based (e.g. ELISA) testing. • Seroconversion is the point of HIV diagnosis, i.e. when the body produces measurable amounts of antibodies • The other methods detect the virus in the blood days before seroconversion: - PCR/NAT – can shorten the window period by 10-12 days. - Antigen Tests (p24) – can shorten the window period by a week
  • 6. The time line from HCV infection to seroconversion • All the different diagnostic tests are antibody based (e.g. ELISA) testing. • Seroconversion is the point of HIV diagnosis, i.e. when the body produces measurable amounts of antibodies • The other methods detect the virus in the blood days before seroconversion: - PCR/NAT – can shorten the window period by 8 week - Antigen Tests (p24) – can shorten the window period by a 6 weeks
  • 7. The solution: SMARTube™ SMARTube™ closes the Window Period - the vast majority of the infected people can be detected within a week from the day of infection
  • 8. HCV window Period With SMARTube™
  • 9. • CE mark. • Israel. • Nigeria. • Russian Federation. • South Africa. • Turkey. • Romania. • Registration in process in several additional countries (Including USA-FDA). • Implementation in testing protocols of FHI and IAVI. • In Process with UN/ WHO/ IFRC. Registration
  • 10. Clinical Data • Israel • Russian Federation • Hungary • Romania • China • South Africa • Kenya • Mexico • Turkey